NGM Biopharmaceuticals, Inc. (NGM) has a consensus analyst rating of Buy, based on 15 analysts covering the stock. Of those, 10 recommend buying, 5 recommend holding, and 0 recommend selling.
The analyst consensus price target for NGM is $16.50, representing a +971.4% upside from the current price of $1.54. Price targets range from a low of $4.00 to a high of $29.00.
